Wednesday, November 22, 2017
Perrigo Company plc announced that it has completed the previously announced divestiture of its Active Pharmaceutical Ingredient (API) business based in Israel to SK Capital for $110 million.
Perrigo's CEO John T. Hendrickson stated, "Today's announcement furthers the strategic review process announced when I became CEO. Actions taken as part of this review process have enabled us to simplify, focus and execute on our core businesses. We continue to look at capital deployment opportunities that drive value for shareholders and further our mission of providing Quality, Affordable Healthcare Products® to consumers around the globe."
